Andrew K. Balo, EVP, Reg. Strategy, Clinical at DEXCOM INC (DXCM), sold 14,019 shares at $72.27 ($1.0M) on 2017-09-11, disclosed to the SEC on 2017-09-13.
Seasonal sale ($1.0M) by EVP, Reg. Strategy, Clinical — this insider has traded DXCM in September in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $71.81 | 3,347 | $240K | 23.8% |
| 2 | $71.81 | 4,184 | $300K | 29.8% |
| 3 | $72.27 | 3,244 | $234K | 23.2% |
| 4 | $72.27 | 3,244 | $234K | 23.2% |
| Total | $72.02 avg | 14,019 | $1.0M | 100% |
| Filing → |
| DXCM | SELL | 2021-07-08 | $2.4M | — | Filing → |
| DXCM | SELL | 2021-06-07 | $897K | — | Filing → |
| DXCM | SELL | 2021-03-12 | $4.0M | — | Filing → |